German Doctors Reject Fund Spending Claims

8 September 1996

Charges by Germany's leading public-sector health funds that patients are being treated unnecessarily in hospitals and clinics instead of being treated as outpatients, wasting billions of Deutschemarks, have been rejected by the clinics and the panel doctors' bodies.

A study undertaken by the funds at the request of Health Minister Horst Seehofer says 10%-20% of the 14 million a year hospital patients could be treated as outpatients just as effectively. Results from three states show that the Hesse funds' medical service says 20% of hospital stays are avoidable, while Saxony-Anhalt puts it at 18%, and Schleswig-Holstein says one in 10 stays is avoidable, rising to one in five for urological treatment.

The claims are rejected by the panel doctors and the German Hospital Association, whose executive director, Joerg Robbers, points out that 80%-90% of patients are referred to hospital by a panel doctor, which means in-patient treatment was thought necessary. Few patients arrive as emergency cases. The patient's age and condition also determines whether treatment is in hospital or not.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight